Premium
One‐year follow‐up of patients treated with new‐generation polymer‐based 38 mm everolimus‐eluting stent: The P38 study
Author(s) -
Sgueglia Gregory A.,
Belloni Flavia,
Summaria Francesco,
Conte Micaela,
Cortese Bernardo,
Silva Pedro Leon,
Ricci Roberto,
Lioy Ernesto,
Pucci Edoardo,
Gaspardone Achille
Publication year - 2014
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.25542
Subject(s) - medicine , mace , restenosis , myocardial infarction , stent , percutaneous coronary intervention , cardiology , target lesion , everolimus , population , surgery , radiology , environmental health
Objectives To assess the clinical outcome at 1‐year follow‐up of real‐world patients with long coronary lesions treated with the 38 mm Xience Prime (Abbott Vascular) everolimus‐eluting stent (EES). Background Long‐lesions present special challenges to the interventional cardiologists, including increased risk of restenosis, periprocedural injury, geographical miss, and stent deliverability. Indeed, results obtained with shorter stent in the treatment of simpler lesions are of limited applicability to longer stents. Methods Consecutive patients presenting with a long coronary lesion treated by percutaneous coronary intervention with at least one implanted 38 mm EES were enrolled in the study. Their clinical data were prospectively registered. Major adverse cardiac events (MACE) were defined as a composite of cardiac death, nonfatal myocardial infarction (according to the Universal Definition) and target vessel revascularization. Stent thrombosis was defined according to the Academic Research Consortium criteria. Results Overall, 203 real‐world patients (152 men, 68 ± 9 years) were enrolled in the P38 Study. At 1‐year follow‐up, 6 (3.0%) patients had died from cardiac causes, 7 (3.4%) had a nonfatal myocardial infarction and 8 (3.9%) underwent target vessel revascularization, yielding a 10.3% cumulative rate of MACE. Two patients had a stent thrombosis (one definite and one probable). No significant differences in event rates were found between patients with and without an additional stent implanted overlapping the 38 mm one. Conclusions The use of a new‐generation polymer‐based 38 mm EES in a real‐world population with unselected long lesions is associated with excellent procedural results and good clinical outcomes at 12‐month follow‐up. © 2014 Wiley Periodicals, Inc.